A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease

Journal of Medicinal Chemistry

Volumn 39, Issue 2, 1996, Pages 392-397

  Sham, Hing L ^a   Zhao, Chen ^a   Stewart, Kent D ^a   Betebenner, David A ^a   Lin, Shuqun ^a   Park, Chang H ^a   Kong, Xiang P ^a   Rosenbrook Jr , William ^a   Herrin, Thomas ^a   Madigan, Darold ^a   Vasavanonda, Suthida ^a   Lyons, Nicholas ^a   Molla, Akhter ^a   Saldivar, Ayda ^a   Marsh, Kennan C ^a   McDonald, Edith ^a   Wideburg, Norman E ^a   Denissen, Jon F ^a   Robins, Terrel ^a   Kempf, Dale J ^a   Plattner, Jacob J ^a   Norbeck, Daniel W ^a   more..

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 DIBENZYL 6 HYDROXY 2,4 BIS(4 HYDROXY 3 METHOXYBENZYL) 3 OXO 1,2,4 TRIAZACYCLOHEPTANE; 4,7 DIBENZYL 2,3,4,5,6,7 HEXAHYDRO 5,6 DIHYDROXY 1,3 BIS[4 (HYDROXYMETHYL)BENZYL] 2H 1,3 DIAZEPIN 2 ONE; A 98881; ANTIVIRUS AGENT; INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR; UNCLASSIFIED DRUG; VIRUS ENZYME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CROSS RESISTANCE; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITOR INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; MOLECULAR MODEL; NONHUMAN; RAT; X RAY CRYSTALLOGRAPHY;

BINDING SITES; DRUG RESISTANCE, MICROBIAL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; MODELS, MOLECULAR;

EID: 13344295092     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9507183     Document Type: Article

References (33)

1. Aggleton, P.; O'Reilly, K.; Slutkin, G.; Davies, P. Risking Everything? Risk Behavior, Behavior Change and AIDS. Science 1994, 265, 341-345.
2. Hirsch, M. S.; D'Aquila, R. T. Therapy for Human Immunodeficiency Virus Infection. N. Engl. J. Med. 1992, 328, 1686-1695.
3. Debouck, C.; Metcalf, B. W. Human immunodeficiency virus protease: a target for AIDS therapy. Drug Dev. Res. 1990, 21, 1-17.
4. Norbeck, D. W.; Kempf, D. J. HIV protease inhibitors. Annu. Rep. Med. Chem. 1991, 26, 141-150.
5. Meek, T. D. Inhibitors of HIV-1 protease. J. Enzyme Inhib. 1992, 6, 65-98.
6. Kempf, D. J. Design of symmetry-based, peptidomimetic inhibitors of HIV protease. Methods Enzymol. 1994, 241, 334-354.
7. Vacca, J. P. Design of tight-binding human immunodeficiency virus type 1 protease inhibitors. Methods Enzymol. 1994, 241, 311-334.
8. Thaisrivongs, S. HIV protease inhibitors. Annu. Rep. Med. Chem. 1994, 29, 133-144.
9. Plattner, J. J.; Norbeck, D. W. Obstacles to drug development from peptide leads. In Drug Discovery Technologies; Clark, R , Moos, W. H., Eds.; Ellis Horwood Ltd.: Chiehester, 1990; pp 92-126.
10. Vacca, J. P.; Dorsey, B. D.; Schlief, W. A.; Levin, R. B.; McDaniel, S. L., Darke, P. L.; Zugay, J.; Quintero, J. C.; Blahy, O. M.; Roth, E.; Sardana, V. V.; Schlabach, A. J.; Graham, P. I.; Condra, J. H ; Gotlib, L.; Holloway, M. K.; Lin, J.; Chen, I.-W.; Ostovic, D.; Anderson, P. S.; Emini, E. A.; Huff, J. R. An orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 4096-4100.
11. Kempf, D.; Marsh, K. C.; Denissen, J. F.; McDonald, E.; Vasavanonda, S.; Flentge, C. A.; Green, B. G.; Fino, L.; Park, C. H.; Kong, X.-P.; Wideburg, N E.; Saldivar, A.; Ruiz, L.; Kati, W. M.; Sham, H. L.; Robins, T.; Stewart, K. D.; Hsu, A.; Plattner, J. J , Leonard, J. M.; Norbeck, D W. ABT-538 is a potent inhibitor of human immunodeficiency virus protease with high oral bioavailability in humans. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 2484-2488.
12. Erice, A.; Balfour, H. H., Jr. Resistance of human immunodeficiency virus type 1 to antiretroviral agents: a review. Clin. Infect. Dis. 1994, 18, 149-156.
13. Kemp, S. D.; Harrigan, P. R.; Kinghorn, I.; Kohli, A.; Larder, B. A Antiviral potency of AZT+3TC combination therapy in vivo supports in vitro virological observations. 2nd International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, November 1994; Abstract P8.
14. Markowitz, M.; Mo, H.; Kempf, D. J.; Norbeck, D. W.; Erickson, J W., Ho, D. D. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 1995, 69, 701-706.
15. Lam, P. Y. S.; Jadhav, P. K.; Eyermann, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Won, Y. N.; Chang, C.-H.; Weber, P. C.; Jackson, D. A.; Sharpe, T R ; Erickson-Vittanen, S. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science 1994, 263, 380-384.
16. Similar compounds have been reported in patent applications W09502582 and W09422840.
17. Sham, H. L.; Betebenner, D. A.; Zhao, C.; Wideburg, N. E.; Saldivar, A.; Kempf, D. J.; Plattner, J. J.; Norbeck, D. W. Facile Synthesis of potent HIV-1 protease inhibitors containing a novel pseudo-symmetric dipeptide isostere. J. Chem. Soc., Chem. Commun. 1993, 1052-1053.
18. Dutta, A. S.; Morley, J. S. Preparation of α-aza-amino-acid (carbazic acid) derivatives and intermediates for the preparation of α-aza-peptides. J. Chem. Soc., Perkin Trans. I 1975, 1712-1720.
19. 1 benzyl side chain is attached, 65.0 ppm). Details of this analysis will be published elsewhere.
20. Miller, M.; Jaskolski, M.; Rao, J. K. M.; Leis, J.; Wlodawer, A. Crystal structure of a retroviral protease proves relationship to aspartic protease family. Nature 1989, 337, 576-579.
21. A complex of compound 7f and HIV-1 protease was crystallized in the P61 space group, a = b = 63.08 Å and c = 83.68 Å. A model for the complex was refined to completion with data extending from 10.0 to 1 8 Å in resolution: The R value for the final model is 0.201, and the rms deviations from ideal bond distances and angles are 0.014 A and 3.1°, respectively. The coordinates have been deposited with the Protein Data Bank (PDB), with the ID code 1PRO. Full details of the crystallographic analysis will be published elsewhere.
22. Ghosh, A. K.; Thompson, W. J.; Fitzgerald, P. M. D.; Culberson, J. C.; Axel, M. G.; McKee, S. P.; Huff, J. R.; Anderson, P. S. Structure-based design of HIV-1 protease inhibitors: replacement of two amides and a 10α-aromatic system by a fused bistetrahydrofuran. J. Med. Chem. 1994, 37, 2506-2508.
23. Molla, A.; Boucher, C.; Korneyeva, M.; Gao, Q.; Schipper, P.; Lyons, N.; Vasavanonda, S.; Niu, P ; Stewart, K.; Park, C.; Chernyavsky, T.; Kempf, D.; Leonard, J.; Norbeck, D. Evolution of resistance to the protease inhibitor Ritonavir (ABT-538) in HIV infected patients. Fourth International Workshop on HIV Drug Resistance, Sardinia, Italy, July 6-9, 1995; Abstract 69.
24. (a) Korneyeva, M.; Boucher, C.; Niu, P.; Schipper, P.; Lyons, N.; Kempf, D. J.; Leonard, J.; Norbeck, D. W.; Molla, A. Phenotypic and genotypic evolution of HIV-1 in AIDS patients undergoing therapy with the protease inhibitor ABT-538. Abstract I 175.
25. (b) Gao, Q.; Stewart, K.; Park, C.; Dave, A.; Kempf, D. J.; Leonard, J.; Norbeck, D. W.; Molla, A. Specific mutations in HIV-1 protease that confer diminished susceptibility to ABT-538. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, Sept. 17-20, 1995; Abstract I 282.
26. Condra, J. H.; Schleif, W. A.; Blahy, O. M.; Gabryelski, L. J.; Graham, D. J.; Quintero, J. C.; Rhodes, A.; Robbins, H. L.; Roth, E.; Shivaprakash, M.; Titus, D.; Yang, T.; Teppler, H.; Squires, K. E.; Deutsch, P. J.; Emini, E. A. In vivo emergence of HIV-1 variant resistant to multiple protease inhibitors. Nature 1995, 374, 569-571.
27. 2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 1991, 35, 2209-2214.
28. Denissen, J. (Drug Biotransformation Department, Abbott Laboratories). Unpublished results.
29. Matayoshi, E. D.; Wang, G. T.; Krafft, G. A.; Erickson, J. W. Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. Science 1990, 247, 954-958.
30. Morrison, J. F. Kinetics of the reversible inhibition of enzyme-catalyzed reactions by tight-binding inhibitors Biochim. Biophys. Acta 1969, 185, 269-286.
31. Greco, W. R.; Hakala, M. T. Evaluation of methods for estimating the dissociation constant of tight binding inhibitors. J. Biol. Chem. 1979, 254, 12104-12109.
32. Hosur, M. V.; Bhat, T. N.; Kempf, D. J.; Baldwin, E. T.; Liu, B.; Gulnik, S.; Wideburg, N. E.; Norbeck, D. W.; Abbelt, K.; Erickson, J. W. Influence of stereochemistry on activity and binding modes for C2 symmetry-based diol inhibitors of HIV-1 protease. J. Am. Chem. Soc. 1994, 116, 847-855.
33. Knapp, S.; Toby, B. N.; Sebastian, M.; Krogh-Jespersen, K.; Potenza, J. A. Relative reactivity and structures of benzoyltrimethylhydrazine and 1-benzoyl-2-methylpyrazolidine. J. Org. Chem. 1981, 46, 2490-2497.